TITLE

Teva/Active Biotech: laquinimod clinical program moves on

PUB. DATE
July 2007
SOURCE
PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral multiple sclerosis drug to reach the market.
ACCESSION #
25688224

 

Related Articles

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Teva Pharmaceutical Industries Ltd. and Active Biotech AB are to initiate a third Phase III study of laquinimod, following the written agreement reached with the U.S. Food & Drug Administration (FDA) on the Special Protocol Assessment (SPA). The third Phase III...

  • Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p121 

    The article reports on the presentation of data from a study conducted by Teva Pharmaceutical Industries Ltd. and Active Biotech AB on the potential of laquinod in treating multiple sclerosis. The findings of the phase III study suggests the effectiveness of laquinimod in reducing annualized...

  • Teva and Active Biotech announce fast track status for multiple sclerosis drug.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p12 

    The article reports on the announcement made by Teva Pharmaceutical Industries, a generic pharmaceutical company and Sweden-based pharmaceutical company Active Biotech on the fast track designation given by the Food and Drug Administration to the oral laquinimod in the U.S. It cites that oral...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article presents information on the clinical development program of once-daily oral laquinimod from Teva Pharmaceutical Industries Ltd. and Active Biotech AB for the treatment of relapsing-remitting multiple sclerosis (RRMS). The companies are going to start a third Phase III trial of...

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Teva announces encouraging data from Phase III multiple sclerosis study.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p10 

    The article reports on the results of the Phase III glatiramer acetate low-frequency administration (GALA) study on the dosing regimen of glatiramer acetate (GA), a therapeutic agent. GA is contained in COPAXONE or glatiramer acetate injection, which is used to treat relapsing-remitting multiple...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5 

    The author reflects on the gap that exists in the orally administered treatments for relapsing multiple sclerosis (MS). He asserts that laquinomoid, an autoimmune suppressant used for treating relapsing MS, is behind from other oral MS treatments in the clinical trial process. He stresses that...

  • Teva, Active Down Following Laquinimod Phase III Miss. Wall, Tom // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p1 

    The article reports on the decline in stocks of pharmaceutical companies Active Biotech AB and Teva Pharmaceutical Industries Ltd. It states that the decline came as a result of the announcement that laquinimod, an oral multiple sclerosis drug, failed to decrease the annualized relapse rate in...

  • Teva and Active Biotech: Phase III results cast shadow over MS approval.  // PharmaWatch: CNS;Sep2011, Vol. 10 Issue 9, p6 

    The article reports that the initial results from the phase III clinical trials of the laquinimod drug from Teva Pharmaceuticals Srl and Active Biotech AB shows the drug has failed the desired outcome to reduce the annual relapse rate of multiple sclerosis (MS). It says that despite the failure,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics